VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures

Uwe Reuter • 22 May 2020
EAN 2020
Headache Antibodies Erenumab Topiramate
LIBERTY Prevention Treatment Trial Updates

Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses the 2-year interim results of the LIBERTY trial (NCT03096834). This study evaluated the efficacy and safety of erenumab in episodic migraine patients who have unsuccessfully failed other preventive migraine treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Uwe Reuter

3:42
The evolving landscape of migraine treatment and prevention
Uwe Reuter • 22 May 2020
1:18
REGAIN trial of galcanezumab in chronic migraine
Uwe Reuter • 25 Jun 2022
1:13
Discontinuation and reinitiation of migraine treatment with GCRP mAbs
Uwe Reuter • 25 Jun 2022
1:51
Unmet needs in migraine: addressing inter-ictal burden
Uwe Reuter • 25 Jun 2022

Related Videos

5:45
New European Academy of Neurology guidelines for cluster headache treatment
Rigmor Hojland Jensen • 19 Oct 2023
1:36
New cluster headache treatments are needed to better meet the needs of patients
Rigmor Hojland Jensen • 19 Oct 2023
2:25
Challenges facing trigeminal autonomic cephalalgia diagnosis
Elizabeth Leroux • 18 Oct 2023
3:17
Diagnostic criteria for trigeminal autonomic cephalalgias
Elizabeth Leroux • 18 Oct 2023
The content of VJNeurology is intended for healthcare professionals